Stay updated on Daratumumab in Myeloma: First Line & Re-treatment Clinical Trial
Sign up to get notified when there's something new on the Daratumumab in Myeloma: First Line & Re-treatment Clinical Trial page.

Latest updates to the Daratumumab in Myeloma: First Line & Re-treatment Clinical Trial page
- ChecktodayNo Change Detected
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedRevision history updated to add v3.5.0 and remove v3.4.3 from the record history. This is an administrative update to the record-keeping and does not change the study content.SummaryDifference0.1%

- Check22 days agoNo Change Detected
- Check29 days agoChange DetectedVersion 3.4.3 adds Contacts/Locations, Study Design, Study Status, and Recruitment Status. It also updates the recruitment status to Active, not recruiting on 2026-03-05, replacing the previous Recruiting status.SummaryDifference1%

- Check58 days agoChange DetectedRevision: v3.4.2 added to the Record History; removed a government funding lapse notice and Revision: v3.4.1.SummaryDifference0.9%

- Check65 days agoChange DetectedAdded a government funding notice about the NIH Clinical Center's operating status. Updated the site revision to v3.4.1, replacing the previous v3.4.0 revision.SummaryDifference0.9%

- Check72 days agoChange DetectedUI changes include a glossary toggle and color-coded indicators for additions and deletions in the study history, with the revision label updated to v3.4.0. The previously listed No FEAR Act data note and the older revision label (v3.3.4) are superseded by the new formatting.SummaryDifference1%

- Check108 days agoChange DetectedRevision: v3.3.3 was added and the HHS Vulnerability Disclosure link along with Revision: v3.3.2 were removed.SummaryDifference0.2%

Stay in the know with updates to Daratumumab in Myeloma: First Line & Re-treatment Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Daratumumab in Myeloma: First Line & Re-treatment Clinical Trial page.